{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009935","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.431956+00:00","generated_at":"2026-06-17T07:50:48.542241+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Processa Pharma FY2022 net loss $27.4M; cash raised to $12.9M; NGC-Cap Phase 2B to start H2 2023","bullets":["Net loss for year ended Dec 31, 2022 was $27.4M ($1.70 per share) vs $11.4M ($0.75) in 2021, including $7.3M non-cash intangible impairment.","Cash of $6.5M at year-end; subsequently raised $6.4M net from registered direct offering, total $12.9M expected to fund operations into Q3 2024.","R&D expenses $11.5M (2022) vs $6.9M (2021); G&A $8.8M vs $4.7M, driven by stock-based comp and trial costs.","FDA meeting in mid-April to discuss Next Generation Capecitabine Phase 2B trial; initiation expected H2 2023 in colorectal cancer.","Dose escalations for NGC-Cap continue with no adverse events; Phase 2A gastroparesis trial completed, out-licensing for non-oncology assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009935","json":"https://secwatch.observer/filing/0001493152-23-009935.json","markdown":"https://secwatch.observer/filing/0001493152-23-009935.md","text":"https://secwatch.observer/filing/0001493152-23-009935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/0001493152-23-009935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:50:48.542241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04a8f58e61d96eacd9d16330f22cbced7bf221e0","claim":"Processa Pharmaceuticals, Inc. reported year ended December 31, 2022 results: net income $27.4 million, or $1.70 per share, EPS $1.70 per share.","evidence_excerpt":"Our net loss for the year ended December 31, 2022 was $27.4 million, or $1.70 per share, compared to a net loss of $11.4 million, or $0.75 per share for the same period of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/0001493152-23-009935-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Net income","value":"$27.4 million, or $1.70 per share"},{"label":"EPS","value":"$1.70 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}